All GLG News Analyses Filed Under: Oncology

Roche's Herceptin provides impressive survival benefit

September 25, 2009

Analysis by: GLG Expert Contributor

Analysis of:Roche's Herceptin provides impressive survival benefit in HER2-positive advanced gastric cancer | www.pharmabiz.com

A detailed analysis of the phase-III ToGA study revealed an unprecedented survival benefit for patients whose tumours exhibited a particularly high level of HER2 when Roche's Herceptin (trastuzumab) was added to standard chemotherapy (Xeloda or intravenous 5-FU and cisplatin). Based on the significant findings of the ToGA study.

Donald FlemingDivision Head of Hematology and OncologyDAVIS HEALTH SYSTEM INC

Farletuzumab (F) helps the ovarian cancer patients that do well, do well?

September 25, 2009

Analysis of:Farletuzumab Data Presented on Phase II Clinical Trial in First-Relapsed Ovarian Cancer Subjects | www.pipelinereview.com

F recently demonstrated a great majority of platinum sensitive patients respond when given in combination with a platinum based regimen in recurrent ovarian caPlatinum sensitive patients typically do well with platinum based intervention, but it's the platinum resistant ( denovo or delayed) that we have a problem with

Donald FlemingDivision Head of Hematology and OncologyDAVIS HEALTH SYSTEM INC

Herceptin for Her2 + gastric cancer, If you can find one

September 25, 2009

Analysis of:Roche's Herceptin provides impressive survival benefit in HER2-positive advanced gastric cancer | www.pharmabiz.com

Herceptin recently reported in Phase II ASCo data to enhance chemo in Her 2 positive gastric cancer

Donald FlemingDivision Head of Hematology and OncologyDAVIS HEALTH SYSTEM INC

REGORAFENIB joins a crowd of TKI's for RCC

September 25, 2009

Analysis of:Bayer's anti-cancer drug regorafenib shows stabilization or regression in 81% of kidney cancer patients | www.pharmabiz.com

RCC now has multiple TKI"S either approved or in development for txThe disease control rate seems to be a popular and effective endpoint to get drugs for RCC approved

Rituxan tests positive in Phase III trial

September 19, 2009

Analysis by: GLG Expert Contributor

Analysis of:Rituxan tests positive in Phase III trial | www.fiercepharma.com

1200 patients with folliclar lymphoma treated with chemotherapy followed by maintenance Rituxan had a longer survival than thos not given Rituxan maintenance.

Bayer and Algeta Enter Global Agreement

September 12, 2009

Analysis by: GLG Expert Contributor

Analysis of:Bayer and Algeta Enter Global Agreement for Development and Commercialization of Treatment for Bone Metastases in Cancer Patients | www.pipelinereview.com

Bayer has entered into a global agreement with Algeta for the development and commercialization of Alpharadin, a novel alpha-emitting radiopharmaceutical, based on radium.

Rossana BerardiConsultant Medical OncologistUNIVERSITA' POLITECNICA DELLE MARCHE

Cost will be the tricky point...

August 22, 2009

Analysis of:IRESSA (Gefitinib) Receives Marketing Authorisation for the Treatment of Non-Small Cell Lung Cancer in Europe | www.pipelinereview.com

I believe that, considering the other available agents, gefitinib could be prescribed to up to 1/3 of NSCLC patients...

Roche's Avastin FDA Approved for Metastatic Kidney Cancer

August 4, 2009

Analysis by: GLG Expert Contributor

Analysis of:Roche's bevacizumab gets US FDA nod to treat the most common type of kidney cancer | www.pharmabiz.com

The FDA approved Avastin for use in patients with metastatic renal cancer in combination with interferon.  The approval was based on data indicating a progression free survival benefit..

Mortality risk low 15 years after radical prostatectomy

July 29, 2009

Analysis by: GLG Expert Contributor

Analysis of:Mortality risk low 15 years after radical prostatectomy | benkazie.wordpress.com

http://benkazie.wordpress.com/2009/07/29/mortality-risk-low-15-years-after-radical-prostatectomy/ The fact remains that prostate cancer kills almost 30,000 men each year. It is also true that we are getting better at making more educated guesses regarding which men are most at risk to progress with prostate cancer.  Finally, it has long been true that radical prostatectomy has been felt to be superior to all other forms of treatment in terms of achieving a long term cure of prostate cancer .

Researchers Identify Gene That May Identify Patients At Risk For Metastases

July 27, 2009

Analysis by: GLG Expert Contributor

Analysis of:Colorectal Cancer - MDC Researchers Identify Genetic Markers For Metastasis Formation | www.medicalnewstoday.com

Researchers in German have identified 115 genes that may help identify patients at increased risk of developing metastatic colorectal cancer. Of these genes, one gene, BAMBI, is more active in metastatic colorectal cancer than in local disease.

Previous Page : 12345678910Next11 to 20 of 900